Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Allen Institute
Headquarters: Seattle, WA, United States of America
Website: http://www.alleninstitute.org...
Year Founded: 2003
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 26, 2025
Discovery & Translation
Science Spotlight: New insight into LAG3’s checkpoint function
BioCentury’s roundup of translational innovations also includes a blood-based T cell assay for T1D, a degrader using a new E3 ligase, and papers from newcos
BioCentury | Feb 28, 2025
Product Development
Rare Disease Spotlight: A genetic seizure disorder with a growing market, pipeline
As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies
BioCentury | Jul 28, 2022
Finance
July 28 Quick Takes: Merck to expand Keytruda’s reach as sales top $5B
Plus venture rounds for BridGene, Ozette and updates from argenx, Elevation-CSPC and more
BioCentury | Dec 18, 2021
Management Tracks
Tong Zhang joins Jing Li at VelaVigo
Plus: Coherus, Allen Institute, Transcenta
BioCentury | Nov 19, 2021
Management Tracks
Zhang becomes CSO at Aspen
Plus: PhaseBio, LifeSprout, Rejuveron and Aerami
BioCentury | Feb 9, 2021
Management Tracks
Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more
Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) said Chairman James Mullen will succeed Cynthia Collins as CEO after she steps down on Feb. 15. Collins had held the role since August 2019.
BioCentury | Jan 8, 2021
Management Tracks
Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute
Corinne Le Goff will join Moderna Inc. (NASDAQ:MRNA) as chief commercial officer on Jan. 19, in the midst of the mRNA company’s launch of its COVID-19 vaccine. Moderna COVID-19 vaccine
BioCentury | Jun 27, 2020
Translation in Brief
Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more
BioCentury’s roundup of preclinical news
BioCentury | Jun 23, 2020
Tools & Techniques
AI tools against COVID-19: a view from where the rubber hits the road
A conversation on bias, speed and accuracy in AI approaches against COVID-19
BioCentury | Jun 5, 2020
Finance
With $85M series B, Athira seeks to recover neuronal health in Alzheimer’s patients
Items per page:
1 - 10 of 19